# University of Oxford

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/university-of-oxford/

## Facts

| Field | Value |
| --- | --- |
| Country | GB |
| Description | Collegiate research university in Oxford, England (Est. 1096) |
| OpenAlex ID | https://openalex.org/F4320320290 |
| ROR ID | https://ror.org/052gg0110 |
| Works | 69,258 |

## Funder papers

- [Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival](https://scholariq.org/papers/effect-of-delayed-targeted-intraoperative-radiotherapy-vs-whole-breast/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort](https://scholariq.org/papers/effects-of-rare-kidney-diseases-on-kidney-failure-a-longitudinal-analysis-of-the/)
- [Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial](https://scholariq.org/papers/low-dose-spironolactone-and-cardiovascular-outcomes-in-moderate-stage-chronic/)
- [Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <scp>EXSCEL</scp> trial](https://scholariq.org/papers/effect-of-once-weekly-exenatide-on-estimated-glomerular-filtration-rate-slope/)
- [Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial](https://scholariq.org/papers/empagliflozin-reduces-risk-of-hospitalization-in-patients-with-chronic-kidney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.